The FDA Law Blog

JULY 10, 2023

After a firm submits a 510(k) to FDA, FDA will request still more information after a first-pass review. According to the 2 nd Quarter FY2023 MDUFA V Performance Report , FDA issued a request for additional information (AI request) on the first FDA review cycle for 63% to 68% of 510(k)s submitted in FY2018 to FY2022.

FDA 75

FDA Documentation Packaging Communication 75

IDStewardship

MARCH 12, 2023

Memorizing 45+ page document is certainly not a reasonable expectation, but one can certainly walk away with an awareness of general concepts and themes which are relevant. ” Labeling the use of an antibiotic as inappropriate or appropriate cannot simply be done based upon whether it is FDA-approved for a given indication.

Medication Guidelines 299

Medication Guidelines Documentation Labelling Hospitals 299

STAT

DECEMBER 29, 2022

The downfall of Aduhelm, the first new treatment for Alzheimer’s disease in two decades, is largely the story of a drug company choosing to maximize its potential profits at the expense of patients and taxpayers, according to a congressional investigation that cites thousands of pages of internal Biogen documents.

Insurance 98

Insurance Documentation FDA 98

The FDA Law Blog

DECEMBER 4, 2023

Prescribing Red Flags The government alleged that from at least 2017 to April 2021 Defendants knowingly filled controlled substance prescriptions “that raised obvious ’red flags’ of potential abuse or diversion.” If the pharmacist can resolve it, they must make a record of the resolution. Complaint ¶ 55.

Controlled Substances 139

Controlled Substances Documentation Dosage Prescription Filling 139

Pharmaceutical Technology

SEPTEMBER 15, 2022

The top 13 players reported more than 10% revenue growth, with BioNTech (3,834.4%), Moderna (2,199.1%), Pfizer (95.2%) and Regeneron Pharmaceuticals (89.1%) reporting a more than 80% year-on-year (YoY) revenue growth from 2020 to 2021, according to GlobalData’s Pharma Intelligence Centre Companies Database. AbbVie reported a 22.7%

Vaccines 108

Vaccines Documentation Compounding FDA 108

European Pharmaceutical Review

OCTOBER 25, 2023

The document by the Medicines and Healthcare products Regulatory Agency (MHRA), US Food and Drug Administration (FDA) and Health Canada, contains key guidance on predetermined change control plans (PCCPs) for MLMDs.

Documentation 105

Documentation FDA 105

The FDA Law Blog

DECEMBER 11, 2023

Mullen — With comments due on the proposed LDT rule last week, FDA wasted no time updating the Unified Agenda to indicate that a final rule may be published in April ( here ). Under the Administrative Procedure Act, FDA is obligated to address major substantive issues when – and not so much if – it publishes a final rule.

FDA 69

FDA Research Laboratories Documentation 69

The FDA Law Blog

FEBRUARY 28, 2024

This is the third withdrawal of an accelerated approval FDA has performed, following Avastin in 2011 and Makena in 2023. Without commenting on the merits of the decision, it is an interesting window into how FDA may use these new procedures in practice. Tobolowsky & Michelle L.

FDA 59

FDA Documentation Labelling 59

pharmaphorum

NOVEMBER 20, 2020

The announcement is no surprise as earlier this week, Pfizer’s CEO Albert Bourla said the company was preparing to file phase 3 data from the vaccine known as BNT162b2 with the FDA after gathering the required amount of safety data. billion doses by the end of 2021. Feature image courtesy of NIAID/Rocky Mountain Laboratories.

Vaccines 96

Vaccines Documentation FDA 96

The FDA Law Blog

MAY 8, 2023

Javitt — FDA recently published a long-awaited draft guidance aimed at reducing the need for prior FDA authorization of modifications to artificial intelligence/machine learning (AI/ML)-enabled device software functions (ML-DSFs). a) , and related guidance documents (e.g., See 21 CFR 807.81(a)(3) a)(3) and 21 CFR 814.39(a)

FDA 98

FDA Documentation Labelling 98

The FDA Law Blog

OCTOBER 18, 2022

On October 17, 2022, FDA published the list of CDRH proposed guidances for FY 2023 (see here ). These are documents on the A-list, a list of prioritized documents that FDA intends to publish during FY2023. FDA published draft guidances for these topics in December 2021 ( here and here ).

Documentation 52

Documentation FDA Labelling 52

pharmaphorum

NOVEMBER 17, 2022

While the FDA seems to remain sceptical about the clinical benefits of Ardelyx’ chronic kidney disease (CKD) therapy Xphozah – having rejected its marketing application in 2021 – its advisors are more confident abut the drug. The post FDA panel backs Ardelyx CKD drug, despite agency concerns appeared first on.

FDA 52

FDA Documentation 52

European Pharmaceutical Review

SEPTEMBER 2, 2022

The sampling strategy must be supported by sound and properly cited sources whose conclusions must be presented as supportive elements in the study documents. The following four elements of sampling methodology were found to be under-documented in RMM effectiveness studies: Supporting documentation for country/region selection.

Adverse Reactions 96

Adverse Reactions Documentation Medical Schools Packaging 96

Pharmaceutical Technology

APRIL 6, 2023

The US Food and Drug Administration (FDA) has accepted Accord BioPharma’s Biologics Licence Application (BLA) for HLX02 (a proposed trastuzumab biosimilar) to treat HER2 cancer types. Accord BioPharma obtained exclusive rights from Henlius in 2021 for the development and commercialisation of HLX02 in Canada and the US.

FDA 52

FDA Documentation 52

ISPE

MARCH 23, 2023

A True Copy is an exact copy of original documentation that preserves the same content, meaning and attributes of the original. It is an electronic copy maintained in an electronic document management system. This negates the requirement for storage of paper evidence and correct GMP document management of these hardcopy evidences.

Documentation 98

Documentation FDA 98

pharmaphorum

JANUARY 24, 2023

Biogen will have to make the case for its amyotrophic lateral sclerosis (ALS) therapy tofersen to an FDA advisory committee in March before it gets a decision on approval. The FDA started reviewing tofersen in July under its accelerated approval pathway, with a priority review that reflects the continued lack of effective therapies for ALS.

FDA 45

FDA Documentation 45

Pharmaceutical Technology

APRIL 6, 2023

The US Food and Drug Administration (FDA) has released the fourth and final chapter in a series of guidance documents designed to support patient-focused drug development. The guidance also touched upon clinical trial design elements that must be explained, described, or rationalised to the FDA.

FDA 52

FDA Documentation Communication 52

Pharma Marketing Network

APRIL 30, 2021

At this year’s Reuters Pharma Clinical 2021, I joined over 500 global leaders in clinical research as they discussed many of these issues under the theme, “rebuild clinical trials in the image of patient need.”. How do we increase the diversity of clinical trials?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Documentation FDA 52

pharmaphorum

AUGUST 31, 2021

Still, in 2021, we have seen the industry evolve and develop strategies on how to establish a viable ECA. The industry has looked to regulators for guidance, and the Food and Drug Administration (FDA) has been quick to respond. To be clear, there will always be challenges in drug development, and stakeholders are no stranger to this.

FDA 88

FDA Insurance Coverage Documentation Pharmaceutical Companies 88

pharmaphorum

DECEMBER 17, 2020

The company’s lead candidate Tenapanor is a targeted, small molecule therapy currently under FDA review. The company’s lead candidate, Tenapanor, is a targeted, small molecule therapy under FDA review for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

FDA 104

FDA Documentation Patient Care 104

Pharmaceutical Technology

MARCH 30, 2023

In August 2021, MSD was able to convert Keytruda’s accelerated approval for its use in in patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-based chemotherapy, into a full approval. GlobalData is the parent company of Pharmaceutical Technology.

Chemotherapy 52

Chemotherapy Packaging FDA Documentation 52

The FDA Law Blog

OCTOBER 5, 2022

eSTAR employs targeted questions to collect specific data and information and includes applicable links to regulations, relevant guidance documents, and other resources. This has the potential to make the FDA’s review efficient as relevant information is collected upfront. printing to PDF) that states comments will not be sent to FDA.

Documentation 45

Documentation FDA 45

The FDA Law Blog

AUGUST 23, 2023

This blog provides an update on the DHT-related PDUFA VII goals that were targeted for completion in the first two quarters of FDA’s Fiscal Year (FY) 2023, including: By the end of Q2 FY 2023, FDA will establish a DHT framework document to guide the use of DHT-derived data in regulatory decision-makings for drugs and biological products.

FDA 52

FDA Documentation 52

PharmaShots

JUNE 14, 2023

The diagnostic and testing companies have been serving as a pivotal foundation stone of the healthcare sector With a global market value of $165.58B in 2021, the diagnostic and testing market size is anticipated to touch the threshold of $348.75 Varex’s 2022 diagnostic segment revenue increased by 4.69% as compared to 2021.

FDA 56

FDA Hospitals Documentation Patient Care 56

The FDA Law Blog

OCTOBER 24, 2023

Mullen — As of October 1, 2023, all 510(k) submissions, unless exempted, must be submitted to FDA using the electronic Submission Template And Resource ( eSTAR ). Currently, eSTAR is voluntary for medical device De Novo submissions, but FDA has initiated the process of requiring De Novos to be submitted using eSTAR.

FDA 52

FDA Documentation Labelling 52

Pharmaceutical Technology

JANUARY 6, 2023

According to the legal documents , the plaintiffs accused the companies of “violating federal antitrust laws, alleging “per se” and “rule of reason” violations”. 2021 was a year of continued innovation and change in the Biopharmaceutical industry. Gilenya is an oral medication for multiple sclerosis. 10,633,344.

Documentation 97

Documentation FDA Hospitals Dosage 97

The FDA Law Blog

FEBRUARY 29, 2024

156, as added by the 1984 Hatch-Waxman Amendments, for certain FDA-regulated products. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug.

FDA 59

FDA Documentation 59

The FDA Law Blog

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” Existing published VCS may be identified internally by FDA or externally by stakeholders.

FDA 59

FDA Packaging Documentation Communication 59

The FDA Law Blog

MARCH 27, 2023

FDA has been implementing the UDI system with different compliance dates for different types of medical devices to ensure a smooth implementation. The compliance dates were first published in 2013, and subsequently updated in various guidance documents and regulations published by FDA. See 21 CFR 801.40(d).

Packaging 45

Packaging Labelling FDA Documentation 45

ISPE

MAY 9, 2023

Improvements have been observed by various regulatory agencies in Latin America for the acceptance and implementation of international standards—for instance, the ICH Common Technical Document (CTD) format. Additional required information beyond ICH guidelines, or non-value-added documents (e.g., 6, and 2.3.S.7 7 are required.

Documentation 52

Documentation Packaging Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 23, 2022

If the complaint is upheld, Enanta could be in line for a share of Pfizer’s revenues from Paxlovid, expected to make a colossal $22 billion in sales this year, after launching in December 2021.

Compounding 52

Compounding Documentation FDA 52

ISPE

NOVEMBER 2, 2022

Jörg Zimmermann, International Board Chair for 2021–2022 and Vice President, Vetter Development Service, External Affairs, Vetter Pharma-Fertigung GmbH & Co., ISPE continues to build on its mission and commitment to providing content for the industry through guidance documents and its CoPs, including expanding CoP topics. Past Chair.

Documentation 52

Documentation Compounding Communication FDA 52

pharmaphorum

SEPTEMBER 7, 2022

The FDA had approved the drug for use as UC treatment in the US in May 2021. A lifelong condition, UC results in inflamed and ulcerated rectal and colonic lining. However, such biological treatments often come with serious side effects, including deep vein thrombosis (DVT).

Dosage 52

Dosage Documentation Immunization FDA 52

European Pharmaceutical Review

JUNE 24, 2022

The US Food and Drug Administration (FDA) requires that manufacturers establish whether nitrosamines, including NDSRIs, could be present in active pharmaceutical ingredients (APIs) and drug products, using the “three-step mitigation strategy described in the agency’s guidance”. Updated 24 February 2021. 18 November 2021.

FDA 52

FDA Documentation Compounding 52

The Checkup by Singlecare

DECEMBER 1, 2023

Food and Drug Administration (FDA) certifies the Red Dye 40 as safe for human consumption. Apart from Red Dye 40, there are eight other certified color additives approved for use in food by the FDA: Blue No. The FDA has denied any link between the two for years. The controversy surrounding Red Dye 40 The U.S. 1, Blue No.

Labelling 52

Labelling FDA Documentation 52

The Checkup by Singlecare

MAY 28, 2024

According to a 2021 systematic review and meta-analysis , the combination of L-theanine and caffeine has positive effects on short-term sustained attention and overall cognition. That said, the effects of caffeine are well-documented. According to the U.S.

Compounding 78

Compounding Documentation FDA 78

pharmaphorum

NOVEMBER 30, 2020

Biogen has invested heavily in its Alzheimer’s candidate aducanumab, but an FDA advisory committee was unimpressed with the company’s rehashed data for the anti-amyloid drug and voted that it didn’t support efficacy. The post Biogen bulks up pipeline with Sage drugs in $3bn deal appeared first on.

FDA 45

FDA Documentation 45